A Phase 4 interventional study of olanzapine and risperidone in Schizophrenia, Schizoaffective Disorder and Schizophreniform Disorder, sponsored by Eli Lilly and Company. Completed at 34 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2010-02-17.
Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 97 studies testing olanzapine in Schizophrenia — 2 open to participants now, 3 under way, 1 of them phase 3. Olanzapine · Schizophrenia.
Among the 97 studies testing olanzapine in Schizophrenia, this one is the 8th largest by enrollment of the 94 interventional ones that give a count, is one of 9 that started in 2006, is one of 46 in phase 4, and was the 40th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →2 of the 97 studies testing olanzapine in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
By country, each count listing its studies:
Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
97 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 8 · Phase 3 25 · Phase 4 46
First in 1997; this study’s year is marked. 9 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 628 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 114 across the 94 interventional studies. Of the 86 that completed or were terminated, 25 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 97 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
33 studies in Schizophrenia by Eli Lilly and Company: 2 open now, 2 under way, none of them phase 3. Of 31 finished, 9 (29%) have results posted.
Among the 33 studies in Schizophrenia by Eli Lilly and Company, this one is the 3rd largest by enrollment of the 29 interventional ones that give a count, is one of 6 that started in 2006, is one of 16 in phase 4, and was the 21st registered.
Eli Lilly and Company’s Schizophrenia studies by the year they started, since 2001.
2 of the studies testing olanzapine in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03781115University of ArizonaProposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia | 2027-02-10 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 97 studies testing olanzapine in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 33 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The current study has been designed to address the significance of early onset of response prospectively in patients treated with an atypical antipsychotic.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Olanzapine for Not Early Onset response (NEO) patients
Drug: olanzapine
Risperidone for Not Early Onset response (NEO) patients
Drug: risperidone
Risperidone for Early Onset response (EO) patients
Drug: risperidone
10-20 milligrams (mg), oral, daily, 10 weeks.
Also known as: LY170053, Zyprexa
2-6 mg, oral, daily, for 10 weeks.
2-6 mg, oral, daily, 10 weeks
Changes From Study Period II Baseline (Week 0) to Weeks 3, 4, 6, 8, and 12 in Positive and Negative Syndrome Scale (PANSS) Total Score in Early Onset Response and Not Early Onset Response-Risperidone Patients
Assesses positive symptoms, negative symptoms, and general psychopathology specifically associated with schizophrenia. Scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Sum of 30 items is PANSS total score and ranges from 30 to 210. Change = time point - single-blind baseline (Week 0).
Time frame: Weeks 0, 3, 4, 6, 8, 12
Changes From Study Period III Baseline (Week 2) to Weeks 3, 4, 6, 8, and 12 in Positive and Negative Syndrome Scale Total Score in Not Early Onset Response-Risperidone and Not Early Onset Response-Olanzapine Patients
Assesses positive symptoms, negative symptoms, and general psychopathology specifically associated with schizophrenia. Scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Sum of 30 items is PANSS total score and ranges from 30 to 210. Change = time point - double-blind baseline (Week 2).
Time frame: Weeks 2, 3, 4, 6, 8, 12
The Number of Participants in the Early Onset (EO) and Not Early Onset-Risperidone (NEO-RIS) Groups Who Show a 20% or Greater Reduction in Positive and Negative Syndrome Scale (PANSS) Total Score
The number of participants who experienced a 20% or greater reduction in their PANSS Total score during the 12 weeks they were on risperidone.
Time frame: Week 0 to Week 12
The Number of Participants in the Not Early Onset-Risperidone (NEO-RIS) and Not Early Onset-Olanzapine (NEO-OLZ) Groups Who Show a 20% or Greater Reduction in Positive and Negative Syndrome Scale (PANSS) Total Score
The number of not early onset participants who experienced a 20% or greater reduction in PANSS Total Score at any time during the 12 weeks of combined Study Period II and Study Period III.
Time frame: Week 0 to Week 12
Number of Participants in the Early Onset and Not Early Onset-Risperidone Groups Who Show a 50% or Greater Reduction in Positive and Negative Syndrome Scale (PANSS) Total Score From Baseline or Meet 'a Priori' Specified Criteria for Remission
'a priori' specified criteria for remission defined as a score of 3 (mild), 2 (minimal), or 1 (absent) on all of the following 8 PANSS items: delusions, conceptual disorganization, hallucinatory behavior, unusual thought content, mannerisms and posturing, blunted effect, passive/apathetic withdrawal, lack of spontaneity and flow of conversation.
Time frame: Week 0 to Week 12
Number of Participants in the Not Early Onset-Risperidone and Not Early Onset-Olanzapine Groups Who Show a 50% or Greater Reduction in Positive and Negative Syndrome Scale Total Score From Baseline or Meet 'a Priori' Specified Criteria for Remission
'a priori' specified criteria for remission defined as a score of 3 (mild), 2 (minimal), or 1 (absent) on all of the following 8 PANSS items: delusions, conceptual disorganization, hallucinatory behavior, unusual thought content, mannerisms and posturing, blunted effect, passive/apathetic withdrawal, lack of spontaneity and flow of conversation.
Time frame: Week 2 to Week 12
Number of Participants With Psychiatric Hospitalizations in the Early Onset and Not Early Onset-Risperidone Groups
Psychiatric Hospitalizations were measured by the Modified Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ) from which it could be determined the number of patients with a psychiatric episode that required an overnight stay in a hospital.
Time frame: Week 2 to Week 12
Vital Signs - Mean Change From Baseline to 10 Week Endpoint in Body Mass Index
Body mass index is an estimate of body fat based on body weight divided by height squared. Change = Endpoint minus baseline.
Time frame: Week 2 to Week 12
Number of Participants With Treatment-Emergent Abnormal Fasting Laboratory Analytes Reported in >=2% of All Participants
Number of participants who experienced abnormal fasting laboratory values at any time during Study Period III. Laboratory reference ranges are dependent on the patient's gender, origin, and age.
Time frame: Week 2 to Week 12
Mean Change From Baseline to 10 Week Endpoint in Extrapyramidal Symptoms as Measured by the Modified Simpson-Angus Scale
Measures neuroleptic-induced parkinsonism. Total score consists of the sum of 10 items: 7 items (items 1, 3, 4, 7, 8, 9, 10) rated on a 4-point severity scale where 0=normal and 4=extreme, and 3 items (items 2, 5, 6) rated on a 2-point severity scale where 0=normal and 2=definitely abnormal/present. The total score ranges from 0 to 34.
Time frame: Week 2 to Week 12
Mean Change From Baseline to 10 Week Endpoint in Extrapyramidal Symptoms as Measured by the Barnes Akathisia Rating Scale - Total Score
Evaluates akathisia associated with use of antipsychotic medications, includes objective and subjective component plus global impression rating for overall disorder. Components rated on scale of 0 to 3 for objective and subjective items and 0 to 5 for global clinical assessment, for total score of 0 (absence of akathisia) to 11 (severe akathisia).
Time frame: Week 2 to Week 12
Mean Change From Baseline to 10 Week Endpoint in Extrapyramidal Symptoms as Measured by the Abnormal Involuntary Movement Scale (AIMS)- Non-Global Total Score
A 12-item instrument assesses observed abnormal movements in different parts of body. Ten items are scored in a 5-point scale (0 = none/normal, 4 = severe) which evaluates abnormal movements in three main anatomic areas (orofacial area, extremities, and trunk). Two items are yes/no questions regarding dentures. Total scores range from 0 to 42.
Time frame: Week 2 to Week 12
Vital Signs - Mean Change From Baseline to 10 Week Endpoint in Sitting Pulse Rate
Changes from Study Period III baseline to endpoint in sitting pulse rate. Change = Endpoint minus baseline.
Time frame: Week 2 and Week 12
Vital Signs - Change From Baseline to 10 Week Endpoint in Standing Diastolic Blood Pressure
Change from Study Period III baseline to endpoint in standing blood pressure. Change = Endpoint minus baseline.
Time frame: Week 2 and Week 12
Vital Signs - Change From Baseline to 10 Week Endpoint in Standing Mean Arterial Pressure
Change from Study Period III baseline to endpoint in standing mean arterial pressure. Change = Endpoint minus baseline.
Time frame: Week 2 and Week 12
Vital Signs - Mean Change From Baseline to 10 Week Endpoint in Standing Pulse Rate
Change from Study Period III baseline to endpoint in standing pulse rate. Change = Endpoint minus baseline.
Time frame: Week 2 and Week 12
Vital Signs - Mean Change From Baseline to 10 Week Endpoint in Standing Systolic Blood Pressure
Change from Study Period III baseline to endpoint in standing systolic blood pressure. Change = Endpoint minus baseline.
Time frame: Week 2 and Week 12
Vital Signs - Mean Change From Baseline to 10 Week Endpoint in Body Weight
Change from Study Period III baseline to endpoint in body weight. Change = Endpoint minus baseline.
Time frame: Week 2 and Week 12
| Milestone | NEO-OLZ | NEO-RIS | EO-RIS | Risperiodone Open-Label Lead-In |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 628 |
| Completed | 0 | 0 | 0 | 522 |
| Not completed | 0 | 0 | 0 | 106 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 35 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 20 |
| Withdrew: Adverse event | 0 | 0 | 0 | 16 |
| Withdrew: Physician decision | 0 | 0 | 0 | 13 |
| Withdrew: Entry criteria not met | 0 | 0 | 0 | 6 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 6 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 7 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 2 |
| Withdrew: Parent/caregiver decision | 0 | 0 | 0 | 1 |
| Milestone | NEO-OLZ | NEO-RIS | EO-RIS | Risperiodone Open-Label Lead-In |
|---|---|---|---|---|
| Started | 186 | 192 | 144 | 0 |
| Completed | 126 | 134 | 100 | 0 |
| Not completed | 60 | 58 | 44 | 0 |
| Withdrew: Lost to follow-up | 14 | 16 | 14 | 0 |
| Withdrew: Withdrawal by subject | 18 | 14 | 12 | 0 |
| Withdrew: Adverse event | 9 | 10 | 8 | 0 |
| Withdrew: Protocol violation | 3 | 8 | 2 | 0 |
| Withdrew: Physician decision | 6 | 5 | 0 | 0 |
| Withdrew: Entry criteria not met | 4 | 1 | 3 | 0 |
| Withdrew: Lack of efficacy | 4 | 4 | 2 | 0 |
| Withdrew: Parent/caregiver decision | 0 | 0 | 2 | 0 |
| Withdrew: Sponsor decision | 1 | 0 | 1 | 0 |
| Withdrew: Clinical relapse | 1 | 0 | 0 | 0 |
Assesses positive symptoms, negative symptoms, and general psychopathology specifically associated with schizophrenia. Scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Sum of 30 items is PANSS total score and ranges from 30 to 210. Change = time point - single-blind baseline (Week 0).
| units on a scale | NEO-RIS | EO-RIS |
|---|---|---|
| Change from Week 0 to Week 3 | -11.90 ± 1.15 | -30.80 ± 1.23 |
| Change from Week 0 to Week 4 | -14.81 ± 1.16 | -32.53 ± 1.24 |
| Change from Week 0 to Week 6 | -16.23 ± 1.26 | -32.90 ± 1.36 |
| Change from Week 0 to Week 8 | -18.10 ± 1.31 | -34.10 ± 1.43 |
| Change from Week 0 to Week 12 | -18.62 ± 1.38 | -35.09 ± 1.50 |
Assesses positive symptoms, negative symptoms, and general psychopathology specifically associated with schizophrenia. Scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Sum of 30 items is PANSS total score and ranges from 30 to 210. Change = time point - double-blind baseline (Week 2).
| units on a scale | NEO-RIS | NEO-OLZ |
|---|---|---|
| Change from Week 2 to Week 3 | -6.94 ± 0.82 | -5.85 ± 0.84 |
| Change from Week 2 to Week 4 | -9.82 ± 0.86 | -9.67 ± 0.88 |
| Change from Week 2 to Week 6 | -11.25 ± 0.98 | -13.06 ± 1.02 |
| Change from Week 2 to Week 8 | -13.13 ± 1.00 | -14.73 ± 1.04 |
| Change from Week 2 to Week 12 | -13.53 ± 1.13 | -17.02 ± 1.16 |
The number of participants who experienced a 20% or greater reduction in their PANSS Total score during the 12 weeks they were on risperidone.
| participants | NEO-RIS | EO-RIS |
|---|---|---|
| >=20% Reduction - Yes | 94 | 119 |
| >=20% Reduction - No | 95 | 19 |
The number of not early onset participants who experienced a 20% or greater reduction in PANSS Total Score at any time during the 12 weeks of combined Study Period II and Study Period III.
| participants | NEO-RIS | NEO-OLZ |
|---|---|---|
| >=20% Reduction - Yes | 94 | 94 |
| >=20% Reduction - No | 95 | 85 |
'a priori' specified criteria for remission defined as a score of 3 (mild), 2 (minimal), or 1 (absent) on all of the following 8 PANSS items: delusions, conceptual disorganization, hallucinatory behavior, unusual thought content, mannerisms and posturing, blunted effect, passive/apathetic withdrawal, lack of spontaneity and flow of conversation.
| participants | NEO-RIS | EO-RIS |
|---|---|---|
| >=50% Reduction - Yes | 67 | 87 |
| >=50% Reduction - No | 122 | 51 |
'a priori' specified criteria for remission defined as a score of 3 (mild), 2 (minimal), or 1 (absent) on all of the following 8 PANSS items: delusions, conceptual disorganization, hallucinatory behavior, unusual thought content, mannerisms and posturing, blunted effect, passive/apathetic withdrawal, lack of spontaneity and flow of conversation.
| participants | NEO-RIS | NEO-OLZ |
|---|---|---|
| >=50% Reduction - Yes | 67 | 67 |
| >=50% Reduction - No | 122 | 112 |
Psychiatric Hospitalizations were measured by the Modified Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ) from which it could be determined the number of patients with a psychiatric episode that required an overnight stay in a hospital.
| participants | NEO-RIS | EO-RIS |
|---|---|---|
| Required overnight stay in hospital: Yes | 9 | 10 |
| Required overnight stay in hospital: No | 175 | 127 |
Body mass index is an estimate of body fat based on body weight divided by height squared. Change = Endpoint minus baseline.
| kilogram per square meter | NEO-OLZ | NEO-RIS | EO-RIS |
|---|---|---|---|
| Baseline | 29.97 ± 8.03 | 31.05 ± 8.04 | 31.13 ± 8.77 |
| Change from Baseline | 0.63 ± 1.38 | 0.43 ± 1.45 | 0.10 ± 1.19 |
Number of participants who experienced abnormal fasting laboratory values at any time during Study Period III. Laboratory reference ranges are dependent on the patient's gender, origin, and age.
| participants | NEO-OLZ | NEO-RIS | EO-RIS |
|---|---|---|---|
| Low total bilirubin | 5 | 3 | 2 |
| High creatine phosphokinase | 6 | 1 | 5 |
| High creatinine | 2 | 4 | 3 |
| High hemoglobin A1c | 6 | 7 | 2 |
| Low sodium | 4 | 4 | 4 |
| High prolactin | 7 | 8 | 7 |
Measures neuroleptic-induced parkinsonism. Total score consists of the sum of 10 items: 7 items (items 1, 3, 4, 7, 8, 9, 10) rated on a 4-point severity scale where 0=normal and 4=extreme, and 3 items (items 2, 5, 6) rated on a 2-point severity scale where 0=normal and 2=definitely abnormal/present. The total score ranges from 0 to 34.
| units on a scale | NEO-OLZ | NEO-RIS | EO-RIS |
|---|---|---|---|
| Mean Change From Baseline to 10 Week Endpoint in Extrapyramidal Symptoms as Measured by the Modified Simpson-Angus Scale | -0.06 ± 0.27 | -0.03 ± 0.26 | -0.02 ± 0.16 |
Evaluates akathisia associated with use of antipsychotic medications, includes objective and subjective component plus global impression rating for overall disorder. Components rated on scale of 0 to 3 for objective and subjective items and 0 to 5 for global clinical assessment, for total score of 0 (absence of akathisia) to 11 (severe akathisia).
| units on a scale | NEO-OLZ | NEO-RIS | EO-RIS |
|---|---|---|---|
| Mean Change From Baseline to 10 Week Endpoint in Extrapyramidal Symptoms as Measured by the Barnes Akathisia Rating Scale - Total Score | -0.31 ± 1.99 | -0.13 ± 2.04 | -0.24 ± 1.38 |
A 12-item instrument assesses observed abnormal movements in different parts of body. Ten items are scored in a 5-point scale (0 = none/normal, 4 = severe) which evaluates abnormal movements in three main anatomic areas (orofacial area, extremities, and trunk). Two items are yes/no questions regarding dentures. Total scores range from 0 to 42.
| units on a scale | NEO-OLZ | NEO-RIS | EO-RIS |
|---|---|---|---|
| Mean Change From Baseline to 10 Week Endpoint in Extrapyramidal Symptoms as Measured by the Abnormal Involuntary Movement Scale (AIMS)- Non-Global Total Score | -0.38 ± 1.73 | 0.11 ± 2.07 | -0.16 ± 1.27 |
Changes from Study Period III baseline to endpoint in sitting pulse rate. Change = Endpoint minus baseline.
| beats per minute | NEO-OLZ | NEO-RIS | EO-RIS |
|---|---|---|---|
| Baseline | 80.49 ± 11.57 | 80.84 ± 12.06 | 77.90 ± 11.02 |
| Change from Baseline | -0.98 ± 11.81 | -2.52 ± 11.50 | -0.94 ± 12.82 |
Change from Study Period III baseline to endpoint in standing blood pressure. Change = Endpoint minus baseline.
| mm Hg | NEO-OLZ | NEO-RIS | EO-RIS |
|---|---|---|---|
| Baseline | 78.69 ± 10.01 | 78.57 ± 10.68 | 80.29 ± 10.65 |
| Change from Baseline | 1.01 ± 10.79 | -0.20 ± 9.96 | -1.73 ± 8.92 |
Change from Study Period III baseline to endpoint in standing mean arterial pressure. Change = Endpoint minus baseline.
| mm Hg | NEO-OLZ | NEO-RIS | EO-RIS |
|---|---|---|---|
| Baseline | 93.53 ± 10.24 | 93.81 ± 11.42 | 94.60 ± 10.67 |
| Change from Baseline | 0.68 ± 9.58 | -0.58 ± 10.12 | -1.94 ± 8.13 |
Change from Study Period III baseline to endpoint in standing pulse rate. Change = Endpoint minus baseline.
| beats per minute | NEO-OLZ | NEO-RIS | EO-RIS |
|---|---|---|---|
| Baseline | 85.57 ± 12.83 | 85.32 ± 13.54 | 82.39 ± 11.46 |
| Change from Baseline | -1.13 ± 14.20 | -2.05 ± 13.21 | -0.56 ± 12.40 |
Change from Study Period III baseline to endpoint in standing systolic blood pressure. Change = Endpoint minus baseline.
| mm Hg | NEO-OLZ | NEO-RIS | EO-RIS |
|---|---|---|---|
| Baseline | 123.20 ± 14.02 | 124.30 ± 16.23 | 123.20 ± 13.63 |
| Change from Baseline | 0.01 ± 12.90 | -1.35 ± 14.22 | -2.36 ± 10.78 |
Change from Study Period III baseline to endpoint in body weight. Change = Endpoint minus baseline.
| kilograms | NEO-OLZ | NEO-RIS | EO-RIS |
|---|---|---|---|
| Baseline | 88.28 ± 23.52 | 90.25 ± 22.81 | 90.67 ± 25.39 |
| Change from Baseline | 1.85 ± 3.97 | 1.29 ± 4.25 | 0.30 ± 3.26 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NEO-OLZ | — | 19/186 (10.2%) | — |
| NEO-RIS | — | 12/192 (6.3%) | — |
| EO-RIS | — | 14/144 (9.7%) | — |
| Event | NEO-OLZ | NEO-RIS | EO-RIS |
|---|---|---|---|
| SchizophreniaPsychiatric disorders | 4/186 | 1/192 | 5/144 |
| Suicidal ideationPsychiatric disorders | 4/186 | 2/192 | 4/144 |
| Psychotic disorderPsychiatric disorders | 3/186 | 2/192 | 0/144 |
| Schizoaffective disorderPsychiatric disorders | 3/186 | 1/192 | 0/144 |
| Schizophrenia, paranoid typePsychiatric disorders | 1/186 | 0/192 | 2/144 |
| PneumoniaInfections and infestations | 0/186 | 1/192 | 1/144 |
| DysarthriaNervous system disorders | 0/186 | 0/192 | 1/144 |
| Loss of consciousnessNervous system disorders | 0/186 | 0/192 | 1/144 |
| AgitationPsychiatric disorders | 0/186 | 0/192 | 1/144 |
| AnxietyPsychiatric disorders | 0/186 | 0/192 | 1/144 |
| Event | NEO-OLZ | NEO-RIS | EO-RIS |
|---|---|---|---|
| Weight increasedInvestigations | 20/186 | 10/192 | 4/144 |
| LethargyNervous system disorders | 2/186 | 3/192 | 12/144 |
| InsomniaPsychiatric disorders | 7/186 | 16/192 | 4/144 |
| SedationNervous system disorders | 12/186 | 11/192 | 5/144 |
| SomnolenceNervous system disorders | 5/186 | 11/192 | 6/144 |
| DiarrhoeaGastrointestinal disorders | 2/186 | 10/192 | 4/144 |
| HeadacheNervous system disorders | 9/186 | 8/192 | 7/144 |
| AnxietyPsychiatric disorders | 8/186 | 8/192 | 7/144 |
| Increased appetiteMetabolism and nutrition disorders | 5/186 | 9/192 | 3/144 |
| Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders | 1/186 | 2/192 | 6/144 |
| Age Continuous(years) | NEO-OLZ | NEO-RIS | EO-RIS | Total |
|---|---|---|---|---|
| Mean | 41.84 ± 10.92 | 41.87 ± 11.34 | 41.83 ± 10.88 | 41.85 ± 11.04 |
| Sex: Female, Male(Participants) | NEO-OLZ | NEO-RIS | EO-RIS | Total |
|---|---|---|---|---|
| Female | 66 | 76 | 58 | 200 |
| Male | 120 | 116 | 86 | 322 |
| Race/Ethnicity, Customized(participants) | NEO-OLZ | NEO-RIS | EO-RIS | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 2 | 1 | 4 |
| Asian | 3 | 0 | 0 | 3 |
| Black or African American | 88 | 92 | 54 | 234 |
| White | 80 | 80 | 74 | 234 |
| Hispanic | 14 | 18 | 15 | 47 |
| Region of Enrollment(participants) | NEO-OLZ | NEO-RIS | EO-RIS | Total |
|---|---|---|---|---|
| United States | 173 | 176 | 130 | 479 |
| Argentina | 4 | 5 | 9 | 18 |
| Russian Federation | 9 | 11 | 5 | 25 |
| Diagnosis(participants) | NEO-OLZ | NEO-RIS | EO-RIS | Total |
|---|---|---|---|---|
| Schizophrenia/Schizophreniform Disorder | 140 | 144 | 114 | 398 |
| Schizoaffective Bipolar Disorder | 31 | 25 | 21 | 77 |
| Schizoaffective Depression | 15 | 23 | 9 | 47 |
| Abnormal Involuntary Movement Scale - Non-Global Total Score(units on a scale) | NEO-OLZ | NEO-RIS | EO-RIS | Total |
|---|---|---|---|---|
| Mean | 0.67 ± 1.82 | 0.49 ± 1.48 | 0.44 ± 1.38 | 0.54 ± 1.58 |
| Barnes Akathisia Rating Scale Total Score(units on a scale) | NEO-OLZ | NEO-RIS | EO-RIS | Total |
|---|---|---|---|---|
| Mean | 0.80 ± 1.81 | 0.95 ± 1.97 | 0.54 ± 1.64 | 0.78 ± 1.83 |
| Modified Simpson-Angus Scale(units on a scale) | NEO-OLZ | NEO-RIS | EO-RIS | Total |
|---|---|---|---|---|
| Mean | 0.12 ± 0.29 | 0.14 ± 0.29 | 0.13 ± 0.82 | 0.13 ± 0.50 |
4 further baseline measures are reported on the registry.
The record gives a start of May 2006, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2009, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olanzapine